Pharmaceuticals

Neumora Therapeutics

Neumora Therapeutics released FY2026 Q1 Earnings on May 7, 2026 (EST): Actual Revenue USD 0, Actual EPS -0.2972 USD (Forecast EPS -0.31 USD)

Neumora Therapeutics released FY2025 earnings on March 30 During-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -1.45 (forecast USD -1.4237)

Neumora Therapeutics released FY2025 Q4 earnings on March 30 During-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.3526 (forecast USD -0.3251)

Neumora Therapeutics to release FY2025 Q4 earnings on March 30 during market hours EST, forecasted revenue USD 0, EPS USD -0.3251

Neumora Therapeutics Announces Progress in Neurological and Metabolic Disease Therapies

JPMorgan Analyst Maintains Neumora Therapeutics Sell Rating

Neumora Therapeutics NMRA-511 Early Trial Positive Results Drive Stock Up

Mizuho Reiterates Buy Rating on Neumora Therapeutics

Neumora Therapeutics released FY2025 9 Months Earnings on November 6, 2025 (EST), with actual revenue of USD 0 and EPS of USD -1.0979

Neumora Therapeutics released FY2025 Q3 earnings on November 6, 2025 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.3506 (forecast USD -0.3333)

Neumora Announces Advances in Neuroscience Drug Development

ARCH Venture Partners X, LLC Acquires Common Shares of Neumora Therapeutics Inc.

Analyst Suneja Reiterates Buy Recommendation on Neumora Therapeutics

Suvannavejh and H.C. Wainwright Reaffirm Buy Rating and Price Target for Neumora Therapeutics Inc.

Neumora Therapeutics Launches Phase 1 Clinical Trial for NMRA-898

Suvannavejh Maintains Buy Rating on Neumora Therapeutics with Price Target of $18

Neumora Therapeutics Inc Holds Virtual R&D Day to Showcase Pipeline Progress

Neumora Therapeutics released FY2025 Semi-Annual earnings on August 6 After-Market EST, actual revenue USD 0, actual EPS USD -0.7471

Neumora Therapeutics released FY2025 Q2 earnings on August 6 After-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.33 (forecast USD -0.3697)

Neumora Therapeutics to Release FY2025 Q2 Earnings on August 6 After-Market (EST), Forecast EPS -0.3697 USD

Aditxt

LINKERS INDUSTRIES LIMITED

Freecast

Butterfly Network

CDT Equity

Asia Pacific Wire & Cable

Agape ATP

Bimergen Energy

Horizon Quantum

Defiance Daily Target 2X Long VELO ETF

NMRA

Neumora Therapeutics fell 3.27% in after-hours trading; Eli Lilly rose 0.13% in after-hours trading, with a transaction volume of USD 606,200; Pfizer rose 0.12% in after-hours trading, with a transaction volume of USD 138,400; Novo Nordisk rose 0.53% in after-hours trading, with a transaction volume of USD 88,200

Price Alert

Eli Lilly

Pfizer

Novo Nordisk AS

U.S. stock night market volatility: Neumora fell 3.27% in after-hours trading: core drug pipeline failure, target price halved

SueWallSt is investigating Neumora Therapeutics for potential securities law violations after its navacaprant program failed in two Phase 3 trials, leading to immediate discontinuation and a stock collapse. The firm alleges executives made misleading statements about trial success probabilities and statistical power prior to the failures. Shareholders who suffered losses are encouraged to contact SueWallSt to discuss their legal rights.

PR Newswire

NMRA SHAREHOLDER INVESTIGATION: SueWallSt Investigates Neumora Therapeutics for Possible Securities Law Violations

ADTX

PCSA

CRVO

In Tuesday's after-market session, several healthcare stocks saw significant movement. Lunai Bioworks surged 77.8% to $5.06, while 60 Degrees, MiNK Therapeutics, Processa Pharma, Redhill Biopharma, and SenesTech also posted gains. Conversely, NeOnc Technologies dropped 13.2%, CervoMed fell 11.73%, Neumora Therapeutics declined 10.26%, Aditxt plummeted 10.1%, TELA Bio decreased 9.69%, and Champions Oncology fell 6.25%. Market caps ranged from $3.9 million to $169.4 million.

benzinga_article

Processa Pharmaceuticals

Tela Bio

Senestech

60 DEGREES PHARMACEUTICALS INC C/WTS 12/07/2028 (TO PUR COM)

Neonc Tech

CervoMed

Redhill Biopharma

Lunai Bioworks

60 Degrees Pharmaceuticals

MiNK Therapeutics

Champions Oncology

12 Health Care Stocks Moving In Tuesday's After-Market Session

Levi & Korsinsky has initiated an investigation into Neumora Therapeutics (NMRA) officers and directors following the failure of its navacaprant Phase 3 trials, which caused a nearly 50% stock drop. The firm examines whether prior statements by management regarding clinical progress were misleading, especially given subsequent workforce reductions. Investors who purchased NMRA shares and suffered losses are encouraged to contact the firm for a free evaluation of their potential legal rights.

prnewswire

16:44 ETNeumora Therapeutics Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics (NMRA)

CUPR

RGNT

SNWV

NIVF

During Tuesday's intraday session, several healthcare stocks experienced significant volatility. Gainers included CervoMed (up 133.3%), Neumora Therapeutics (up 46.63%), and NewGenIvf Group (up 36.95%). Conversely, notable losers were SANUWAVE Health (down 42.0%), Cuprina Holdings (down 35.64%), and Regentis Biomaterials (down 29.92%). The report highlights substantial price movements across various NASDAQ-listed companies.

Cuprina

Regentis Biomaterials

SANUWAVE Health

NewGenIvf

Outlook Therapeutics

Conexeu Sciences

PRF Tech

Scilex

Elicio Therapeutics

NEWGENIVF GROUP LIMITED C/WTS 03/04/2029(TO PUR COM)

12 Health Care Stocks Moving In Tuesday's Intraday Session

CAMP

XOMX

XOMZ

XOMO

Wall Street analysts upgraded five stocks on Tuesday. B of A's Jean Ann Salisbury upgraded Exxon Mobil (XOM) to Buy with a $154 target. JP Morgan's Anupam Rama upgraded Camp4 Therapeutics (CAMP) to Overweight, raising the target to $9. B of A's Jeffrey Spector upgraded Extra Space Storage (EXR), W.P. Carey (WPC), and Kilroy Realty (KRC) to Neutral or Buy, with price targets raised to $156, $83, and $44 respectively.

- Top Wall Street analysts have upgraded various stocks, including Exxon Mobil Corp, CAMP4 Therapeutics Corp, Extra Space Storage Inc., W. P. Carey Inc., and Kilroy Realty Corporation.  
- B of A Securities analyst Jean Ann Salisbury raised Exxon Mobil's rating to Buy with a price target of $154, while Anupam Rama of JP Morgan upgraded CAMP4 to Overweight with a target of $9.  
- Other changes included upgrades for Extra Space Storage and W. P. Carey from Underperform to Neutral, with revised price targets indicating potential growth.

CAMP4 Therapeutics

Exxon Mobil

Extra Space Storage

WP Carey

Kilroy Realty

Direxion Daily XOM Bull 2X Shares

Direxion Daily XOM Bear 1X Shares

YieldMax Xom Option Income Strategy ETF

This Exxon Mobil Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Neumora Therapeutics (NMRA) halted development of antidepressant navacaprant after two late-stage trials failed to meet primary endpoints in major depressive disorder patients. 1Neumora Therapeutics (NMRA) cut ~35% staff to save about $10M annually, extending cash runway into Q3 2027; refocusing on NMRA-511, NMRA-898 and NMRA-215 with upcoming data and starts. 2 3Neumora (NMRA) pipeline updates: NMRA-511 MAD cohort in elderly completes Q4 2026 to guide Phase 2b by year-end; NMRA-898 Phase 1 data due H2 2026; NMRA-215 toxicology mid-2026, trials by year-end. 4

TradingView

Key facts: NMRA Halts Navacaprant; 35% cut, Runway Q3 2027; 511/898/215

CYPH

GNPX

TRAW

During Monday's intraday session, several healthcare stocks experienced significant volatility. Regentis Biomaterials surged 370.7% to $7.06, while Cuprina Holdings rose 133.12%. Other gainers included QTREX Quantum, Gelteq, Cypherpunk Technologies, and SAB Biotherapeutics. Conversely, Elicio Therapeutics plummeted 72.1%, followed by Context Therapeutics down 49.93% and Neumora Therapeutics falling 48.32%. Additional decliners were 20/20 Biolabs, Traws Pharma, and Genprex.

Neumora Therapeutics(NMRA.US)